Medindia

X

Shelved bowel-syndrome drug still in demand

by Medindia Content Team on  April 18, 2002 at 1:43 PM General Health News   - G J E 4
Shelved bowel-syndrome drug still in demand
After receiving thousands of letters from desperate patients, the FDA will convene a panel of outside experts to discuss whether Lotronex, an irritable bowel syndrome(IBS) medication, can come back on the market. To meet demand, FDA official Victor Raczkowski says, his agency has expanded time allowed for public testimony at the advisory committee meeting.
Advertisement

IBS, affecting up to 15% of Americans, causes symptoms including lower abdominal pain, a sudden need to have a bowel movement, diarrhoea and constipation. Lotronex was the first new IBS treatment in years and the only one approved for women who mainly have diarrhoea, roughly one-sixth of all IBS patients. Glaxo Wellcome, now GlaxoSmithKline, pulled Lotronex in December 2000, 8 1/2 months after the drug's debut. About 300,000 patients had taken it, according to Glaxo.

Advertisement
In June 2000, the FDA began receiving reports of Lotronex users suffering severe constipation and ischemic colitis, or inflammation of the large bowel, caused by reduced blood flow. By year's end, the FDA had learned of 141 such cases, including 7 deaths, according to the Public Citizen Health Research Group, which had petitioned the agency in September 2000 to withdraw the drug. Glaxo and FDA officials have been meeting regularly since January 2001 to discuss ways of limiting adverse effects.
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All